Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLAW) Stock Overview
Explore Estrella Immunopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
ESLAW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Estrella Immunopharma, Inc. (ESLAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.05.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.64 and a market capitalization of 1.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Cheng Liu
5858 Horton Street, EmeryVille, CA
1970